Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947595611> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2947595611 endingPage "TPS5089" @default.
- W2947595611 startingPage "TPS5089" @default.
- W2947595611 abstract "TPS5089 Background: CCS1477 is a potent, selective and orally bioavailable inhibitor of the bromodomain of p300 and CBP, two homologous and critical co-activators of the androgen receptor (AR) and its variant forms, including mutated, amplified and spliced AR, as well as c-Myc. CCS1477 represents a new therapeutic option for prostate cancer patients who have progressed after failure of anti-androgen therapy and in combination with anti-androgens such as enzalutamide or abiraterone. Methods: This is a Ph I/IIa study to determine the maximum tolerated dose (MTD) and/or recommended Phase II dose and schedule(s) of CCS1477 and investigate clinical activity of CCS1477 monotherapy and CCS1477 in combination with abiraterone or enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC). The trial aims to enrol approximately 150 patients and is currently recruiting in the UK with plans to open additional sites in the USA (NCT03568656). Key inclusion criteria (for the mCRPC) require previous treatment with abiraterone and/or enzalutamide, taxane as well as evidence of disease progression (PCWG-3 guidelines). Single dose and steady state pharmacokinetics will be determined along with changes in plasma PSA, LDH and ALKP and in circulating tumour cell number. Anti-tumour activity will be determined by standard imaging according to PCWG-3 guidelines. Paired tumour biopsies for biomarker assessment are being collected. Cohort 1 of the monotherapy dose-escalation (rolling 6 design; 3-6 patients/cohort) has completed. Enrolment to cohort 2 began in January 2019. Dose finding in combination (CCS1477 + abiraterone; CCS1477 + enzalutamide) will be open once monotherapy dose escalation completes. Following definition of a recommended phase 2 dose and schedule for monotherapy and in combination, three expansion arms in patients with mCRPC will be opened in parallel (25 patients/arm); CCS1477 monotherapy; CCS1477 + abiraterone; CCS1477 + enzalutamide. A further expansion in patients with advanced solid tumours with a mutation in p300 or CBP will also be opened. Clinical trial information: NCT03568656." @default.
- W2947595611 created "2019-06-07" @default.
- W2947595611 creator A5012089778 @default.
- W2947595611 creator A5033962986 @default.
- W2947595611 creator A5048063115 @default.
- W2947595611 creator A5055462632 @default.
- W2947595611 creator A5057264457 @default.
- W2947595611 creator A5057407696 @default.
- W2947595611 creator A5065177684 @default.
- W2947595611 creator A5072987005 @default.
- W2947595611 creator A5083141591 @default.
- W2947595611 date "2019-05-20" @default.
- W2947595611 modified "2023-09-30" @default.
- W2947595611 title "An open label phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination in patients with advanced solid/metastatic tumors." @default.
- W2947595611 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.tps5089" @default.
- W2947595611 hasPublicationYear "2019" @default.
- W2947595611 type Work @default.
- W2947595611 sameAs 2947595611 @default.
- W2947595611 citedByCount "5" @default.
- W2947595611 countsByYear W29475956112021 @default.
- W2947595611 countsByYear W29475956112023 @default.
- W2947595611 crossrefType "journal-article" @default.
- W2947595611 hasAuthorship W2947595611A5012089778 @default.
- W2947595611 hasAuthorship W2947595611A5033962986 @default.
- W2947595611 hasAuthorship W2947595611A5048063115 @default.
- W2947595611 hasAuthorship W2947595611A5055462632 @default.
- W2947595611 hasAuthorship W2947595611A5057264457 @default.
- W2947595611 hasAuthorship W2947595611A5057407696 @default.
- W2947595611 hasAuthorship W2947595611A5065177684 @default.
- W2947595611 hasAuthorship W2947595611A5072987005 @default.
- W2947595611 hasAuthorship W2947595611A5083141591 @default.
- W2947595611 hasConcept C112705442 @default.
- W2947595611 hasConcept C121608353 @default.
- W2947595611 hasConcept C126322002 @default.
- W2947595611 hasConcept C143998085 @default.
- W2947595611 hasConcept C2776551883 @default.
- W2947595611 hasConcept C2777511904 @default.
- W2947595611 hasConcept C2777899217 @default.
- W2947595611 hasConcept C2778971682 @default.
- W2947595611 hasConcept C2780192828 @default.
- W2947595611 hasConcept C2781190966 @default.
- W2947595611 hasConcept C530470458 @default.
- W2947595611 hasConcept C61367390 @default.
- W2947595611 hasConcept C71924100 @default.
- W2947595611 hasConcept C72563966 @default.
- W2947595611 hasConcept C98274493 @default.
- W2947595611 hasConceptScore W2947595611C112705442 @default.
- W2947595611 hasConceptScore W2947595611C121608353 @default.
- W2947595611 hasConceptScore W2947595611C126322002 @default.
- W2947595611 hasConceptScore W2947595611C143998085 @default.
- W2947595611 hasConceptScore W2947595611C2776551883 @default.
- W2947595611 hasConceptScore W2947595611C2777511904 @default.
- W2947595611 hasConceptScore W2947595611C2777899217 @default.
- W2947595611 hasConceptScore W2947595611C2778971682 @default.
- W2947595611 hasConceptScore W2947595611C2780192828 @default.
- W2947595611 hasConceptScore W2947595611C2781190966 @default.
- W2947595611 hasConceptScore W2947595611C530470458 @default.
- W2947595611 hasConceptScore W2947595611C61367390 @default.
- W2947595611 hasConceptScore W2947595611C71924100 @default.
- W2947595611 hasConceptScore W2947595611C72563966 @default.
- W2947595611 hasConceptScore W2947595611C98274493 @default.
- W2947595611 hasIssue "15_suppl" @default.
- W2947595611 hasLocation W29475956111 @default.
- W2947595611 hasOpenAccess W2947595611 @default.
- W2947595611 hasPrimaryLocation W29475956111 @default.
- W2947595611 hasRelatedWork W2094570582 @default.
- W2947595611 hasRelatedWork W2135620818 @default.
- W2947595611 hasRelatedWork W2161225819 @default.
- W2947595611 hasRelatedWork W2274307715 @default.
- W2947595611 hasRelatedWork W2305036325 @default.
- W2947595611 hasRelatedWork W2568045406 @default.
- W2947595611 hasRelatedWork W2776356588 @default.
- W2947595611 hasRelatedWork W2901274396 @default.
- W2947595611 hasRelatedWork W3023947295 @default.
- W2947595611 hasRelatedWork W3132581442 @default.
- W2947595611 hasVolume "37" @default.
- W2947595611 isParatext "false" @default.
- W2947595611 isRetracted "false" @default.
- W2947595611 magId "2947595611" @default.
- W2947595611 workType "article" @default.